Who Can Pfizer Inc. Afford?

Are Bristol-Myers Squibb Co (NYSE: BMY) or Shire PLC (LON:SHP) on Pfizer Inc. (NYSE:PFE)’s shopping list?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

AstraZenecaPfizer (NYSE:PFE.US) has shaken out its piggy bank and put all its pennies on the table… and AstraZeneca (LSE: AZN) (NYSE: AZN.US) has still rejected its offer, saying the latest proposal of £55-a-share “undervalues the company and its attractive prospects”.

Pfizer added a statement that it will not take the bid hostile so the question remains: what will it do with the $69 billion of offshore booty? US Senators are working overtime to close the loophole that allows US companies to undertake inversions. Senator Carl Levin, who is the chairman of a committee which targets corporate tax avoidance, said he will act fast to close the loophole and prevent American companies from moving their domicile to low tax countries.

So the clock is ticking… can Pfizer splash the cash before Uncle Sam comes knocking on the door of its Cayman Island deposit box?

The problem for Pfizer lies in that there are not very many other pharmaceutical companies with its required criteria. It requires a pipeline of drugs that will enhance and expand its own portfolio, operational synergies and an in inversion strategy for tax purposes? 

One biopharmaceutical company being mentioned in more than a few places as a good ‘fit’ for Pfizer is Bristol-Myers Squibb  (NYSE: BMY.US). Bristol-Myers, headquartered in New York and valued at $83 billion and slightly cheaper than AstraZeneca, it has an impressive pipeline of medicines, two of its cancer immunotherapies are already in Phase III trials and one in product market development. However attractive the company’s pipeline, it will not give Pfizer the required tax shelter and Chief Executive Officer Ian Read said Pfizer would not consider a US acquisition, given its high tax rates.

Pfizer can avoid repatriation taxes by buying Shire (LSE:SHP). Shire is a company that manufactures pharmaceuticals and looks like a prime candidate for a takeover. Speculators moved in some weeks ago: Allergan has approached Shire in recent months and reportedly made a preliminary offer giving it a valuation of $33 billion — small change for Pfizer…

Shire is Jersey-registered and has its tax domicile in Ireland. Ireland has been attractive for multinationals because it has a low rate of only 12.5% corporation tax. The sweetener for a UK base, however, comes in the form of the tempting “patent box” tax incentives, which attribute a 10 per cent corporation tax rate to profit earned on products patented in the UK.

The AstraZeneca board reportedly signalled that they would be happy to open negotiations with Pfizer for an additional 10% on its last offer of £55-a-share, but stock market rules reduce any wriggle room to keep open negotiations. The deadline for Pfizer is the 26 May to state its intentions, otherwise they cannot offer a revised bid for six months. This could be enough time for US senators to implement legislation that could halt Pfizer’s ambition to become a UK domicile company.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Lisa Walls-Hester does not own any shares in the above companies.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »